Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02879760
Title Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Turnstone Biologics, Inc.
Indications

lung non-small cell carcinoma

Therapies

Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.